A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Lindsay Masters stayed behind, very likely in the knowledge that he might soon be running the company as Heseltine's political career took off. However, Heseltine continued as managing director of Haymarket even after being elected to Parliament in March 1966, and based himself at the company offices near Oxford Circus rather than in the House of Commons. Heseltine's Oxford friend Julian Critchley was editor of Town for around a year from 1966 until he was sacked by Masters, ending his friendship with Heseltine who had shrunk from delivering the blow himself.
=== BASDAI === The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), developed in Bath (UK), is an index designed to detect the inflammatory burden of active disease. The BASDAI can help to establish a diagnosis of AS in the presence of other factors such as HLA-B27 positivity, persistent buttock pain which resolves with exercise, and X-ray or MRI-evident involvement of the sacroiliac joints. It can be easily calculated and accurately assesses the need for additional therapy; a person with AS with a score of four out of a possible 10 points while on adequate NSAID therapy is usually considered a good candidate for biologic therapy. The Bath Ankylosing Spondylitis Functional Index (BASFI) is a functional index which can accurately assess functional impairment due to the disease, as well as improvements following therapy. The BASFI is not usually used as a diagnostic tool, but rather to establish a baseline and subsequent response to therapy.
At the Congress of Vienna of 1814–1815, Austria's representative, Prince von Metternich, detected a threat to this status quo in the Austrian Empire through nationalists' demands for independence from the empire. While Vienna's subjects included numerous ethnic groups (such as Germans, Italians, Romanians, Hungarians, etc.), the Slav proportion of the population (Poles, Ruthenians, Ukrainians, Czechs, Slovaks, Slovenes, Serbs, Bosniaks, and Croats) together formed a substantial—if not the largest—ethnic grouping.
In 1911, he entered St Peter's College, Adelaide, where he excelled in chemistry, physics, mathematics and history. He played various sports for the school: cricket, Australian football, tennis, and track and field athletics as a sprinter and high jumper. The cost of his education was covered by four scholarships. He served in the Senior Cadets, in which he was commissioned as a second lieutenant in August 1916. After the First World War broke out in 1914, he wished to enlist, but parental permission was required and was not forthcoming. He was head boy in his final year at school, and was ranked twelfth in the state in his final examinations. Rather than become a businessman like his father, Florey elected to follow in the footsteps of his sister Hilda, who studied medicine. He entered the University of Adelaide in March 1917, his fees paid entirely by a state scholarship. This allowed him to continue his studies after his father died from a heart attack on 15 September 1918, and the shoe company was found to be insolvent and went into liquidation. Coreega and other properties had to be sold, and in 1920, the family moved into a bungalow in Glen Osmond. Florey participated in university athletics and tennis. He was an editor of the Medical Students' Society's Review and the Adelaide University Magazine. It was through the latter that he met Mary Ethel Hayter Reed, a fellow medical student, when he asked her to contribute an article on Women in Medicine.
Weak affinity chromatography (WAC) is an affinity chromatography technique for affinity screening in drug development. WAC is an affinity-based liquid chromatographic technique that separates chemical compounds based on their different weak affinities to an immobilized target. The higher affinity a compound has towards the target, the longer it remains in the separation unit, and this will be expressed as a longer retention time. The affinity measure and ranking of affinity can be achieved by processing the obtained retention times of analyzed compounds. Affinity chromatography is part of a larger suite of techniques used in chemoproteomics based drug target identification. The WAC technology is demonstrated against a number of different protein targets – proteases, kinases, chaperones and protein–protein interaction (PPI) targets. WAC has been shown to be more effective than established methods for fragment based screening. Affinity chromatography was conceived and first developed by Pedro Cuatrecasas and Meir Wilchek.
Sources: en.wikipedia.org
=== Synthesis === The vast majority of the neptunium that currently exists on Earth was produced artificially in nuclear reactions. Neptunium-237 is the most commonly synthesized isotope due to it being the only one that both can be produced via neutron capture and also has a half-life long enough to allow weighable quantities to be easily isolated. It is by far the most common isotope to be utilized in chemical studies of the element.
The thiazolidinediones , abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, are a class of heterocyclic compounds consisting of a five-membered C3NS ring. The term usually refers to a family of drugs used in the treatment of diabetes mellitus type 2 that were introduced in the late 1990s. As of 2024, there are two FDA-approved drugs in this class, pioglitazone and rosiglitazone.
==== Abkhaz attack ==== With respect to the war's second theater, the report found the joint Abkhaz-Russian attack on the Kodori Gorge was unjustified under international law and was an illegal use of force. The commission noted that the Abkhaz preparation of military operation in the upper Kodori Valley was acknowledged by the Russian officials and Abkhaz deployment in the lower Kodori Valley "reportedly" began already on 6 August 2008. According to the commission, since "the upper Kodori Valley did not belong to Abkhaz-controlled territory under the provisions of the Moscow Agreement", the attack "must therefore be qualified as use of force prohibited by Art. 2(4) of the Charter and moreover as an “armed attack” on Georgia in the sense of Art. 51 of the UN Charter." The commission said Russian support of Abkhazia "could not be justified as collective self-defence in favour of Abkhazia, because third-party involvement in an internal military conflict in support of the seceding party is not allowed". The commission concluded: "The use of force by Abkhazia was not justified under international law and was thus illegal. The same applies to the Russian support for Abkhaz use of force." General Russian involvement in the conflict in Georgia was "a violation of the fundamental international legal prohibition of the use of force."
=== Pro-101-1 (thermal burns) === Pro-101-1 is a topical PDGF-BB gel candidate for the treatment of thermal burns. The company received approval from China's National Medical Products Administration (NMPA) to commence Phase IIa clinical trials in June 2022, which were completed in May 2023. The Phase IIb clinical trial reached last patient out in April 2025, and the clinical report for deep second-degree burns was finalised in December 2025. As of May 2026, Pro-101-1 had enrolled the first patient in its Phase IIIa clinical trial for deep second-degree burns in China. The U.S. FDA has confirmed that Pro-101-1 is eligible for approval via the Section 351(a) biologics BLA pathway.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.